Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Do you really want to delete this prezi?
Neither you, nor the coeditors you shared it with will be able to recover it again.
Make your likes visible on Facebook?
You can change this under Settings & Account at any time.
Transcript of Gene Therapy
Muscular Dystrophy Most common approach : insert a normal copy of a gene into a diseased cell to compensate for the mutated one Targeted Cells Somatic Cell line
Germ Cell line GENE THERAPY Hala Al-Hafez
Alyssa Pastic Candidate for Gene Therapy? 3) Do we know the affected tissues? 4) Do we know how the mutation affects protein function? 5) Will adding a normal copy of the gene solve the problem? 1) Is it a genetic condition? 2) Do we know the sequence of the gene? 6) Is the tissue accessible? If all conditions are met, gene therapy can be used! Vectors Viral Vectors Non-viral Vectors Retrovirus Adenovirus Adeno-associated virus Adenovirus
Double stranded DNA
Targets dividing and non-dividing cells
DNA does not integrate into host genome
Size is 7-8 kilobases Retrovirus
Single stranded RNA
Targets only dividing cells
Integrates RANDOMLY into the host genome
Genome size is 7-8 kilobases Naked DNA Naked DNA
Circular double stranded DNA
Does not integrate into host genome Lipoplex Lipoplexes
Artificial vesicles composed of a lipid bilayer
Contains DNA of interest
Does not integrate into host genome Adeno-associated Virus
Single stranded DNA
Targets dividing and non-dividing cells
May insert into a specific region in chromosome 19
Dependent on helper virus
Genome size is 4-5 kilobases Pros of Viral Vectors Pros: More efficient in transfection
More easily targeted to specific tissues
Potential long term effect Cons: Potential to trigger an immune response
Limited to the size of the genome Methodology 1) Production of the viral vectors: Therapeutic gene is obtained
Pathogenic genes removed from virus
Therapeutic gene is ligated into viral genome
Recombinant viral genome inserted into "package cell lines"
"Package cell lines" mass produce non-pathogenic viruses that have the therapeutic gene
Cells are lysed and centrifuged to isolate viruses
Viruses are injected into diseased cells HEK293 cells 2) Deliver and target specific cells: Engineer surface proteins to target specific cells
Can inject in two ways :
Cell infection is by endocytosis or membrane fusion Large Scale Paper Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo Palomeque et al., 2007 Gene Therapy ,14: 989-997 Background
Gene therapy is a great treatment option for heart malfunctions.
AAV's can have different tissue targets determined by:
specific affinity for extracellular matrices Purpose To look at the efficiency of 8 different adeno-associated viruses in transfecting heart cells. Method LacZ was inserted as the "therapeutic gene"
8 different serotypes of AAV were injected into rat hearts to see which ones were best suited to transfect heart cells 3 tests were used to determine transduction efficiency of each serotype:
luminometer -> bioluminescent assay
blue/white test -> digested indole turns blue
qPCR of LacZ and AAV capsid genes
Each method was tested 1, 4, 12, and 24 weeks after transfection Results AAV5 was interesting because it was not previously known to target heart cells because the only other study of it involved GFP localization for analysis (LacZ insertion proved to be more accurate!).
No NAb's were found against any of the serotypes (which is good in rats, but maybe not in other organisms..?) Small Scale Paper Adenoviral delivery of human CDC5 promotes G2/M progression and cell division in neonatal ventricular cardiomyocytes
Williams et al., 2006
Gene Therapy, 13: 837-843 Background Cardiomyocytes are heart muscle cells
Cell division in cardiomyocytes ceases in neonatal period hence, no regeneration
Cardiomyocyte death causes an indefinite decrease in functional capacity
To determine whether recombinant adenoviruses can be used to overexpress hCDC5 in conjunction with E1A and E1B in cardiomyocytes in an attempt to induce cell division In past research:
Terminally differentiated cardiomyocytes have been induced to re-enter the cell cycle by overexpression of E1A and E1B viral proteins
BUT – these cells could not move past G1/S phase, DNA synthesis was achieved but entry into G2 and mitosis was blocked
New research: Cell division cycle -5 protein (hCDC5) is necessary for G2 progression and mitosis entry Purpose Methods E1A, E1B and hCDC5 genes were packaged into non-virulent adenoviral serotype 5 vectors
The vectors were injected into rat cardiomyocytes (ex vivo)
Successful transfection and expression of recombinant E1A, E1B and hCDC5 in cardiomyocytes verified by RT-PCR and immunoblot assays Results Overexpression of E1A/E1B and hCDC5 caused:
Nuclear localization of cyclin-dependant kinase 1 and cyclin B1
Increase in number of cardiomocyte nuclei
Increase in mitotic index
Increase in cardiomyocyte cell number Conclusions Overexpression of hCDC5 together with E1A and E1B can successfully drive cardiomyocytes through cell division
Potential treatment for heart disease patients in the future?
HOWEVER – cell numbers suggest that only one round of cell division occurred, so adenoviral vectors would have to be administered after every cell division in order for this treatment to be effective Limitations of Gene therapy Everything about the gene must be known
Potential for vector insertion into non-target cells
Regulation of gene expression is extremely complex
Risk of re-incorporation or reversion of pathogenic genes
Retroviruses insert at random
Ethics and Cost Advantages of Gene Therapy Treat problem from the root
Potentially no side effects
Potential to treat diseases that are not curable by drugs Thank you for listening!
Hope you enjoyed it. Limitations: Advantages: Cardiovascular disease is often caused by a decrease in contractile ability.
Contractile dysfunction is caused by mutations in genes that code for calcium handling proteins and other ion pumps in heart cells. AAV8 was most successful, while AAV3 and 4 were least efficient AAV8 was the only one that did not plateau (transfection efficiency) before the end of the experiment (proves that humoral immunity [genetic reversion] was not an issue for AAV8)
AAV 2 and 5 showed a slight decrease after the plateau (indicating possible humoral immunity). Serotypes 7 and 8 were shown to have different distributions within cryosections compared to the others, indicating specific tropism within the heart Cons of viral vectors